DXCM SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against DexCom, Inc. (DXCM)

Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for allegedly making false and misleading statements regarding its G6 and G7 continuous glucose monitoring systems, which may have posed health risks to users [1][2]. Allegations Against DexCom - Defendants allegedly made unauthorized design changes to the G6 and G7 systems that compromised their reliability and safety [2]. - The enhancements claimed for the G7 device were reportedly overstated, leading to potential health risks for users relying on these devices for accurate glucose readings [2]. - DexCom is accused of downplaying the severity of issues related to the G7 devices, which could result in increased regulatory scrutiny and significant legal and financial repercussions [2]. Lead Plaintiff Process - Investors in DexCom have until December 26, 2025, to seek appointment as lead plaintiff representatives in the class action, which involves directing the litigation on behalf of all class members [3]. - The lead plaintiff is typically the investor or group of investors with the largest financial interest in the case [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].